ATE450256T1 - Verwendung von zusammensetzungen enthaltend kappa-opioidrezeptor-antagonisten zur behandlung von dissoziativen störungen - Google Patents

Verwendung von zusammensetzungen enthaltend kappa-opioidrezeptor-antagonisten zur behandlung von dissoziativen störungen

Info

Publication number
ATE450256T1
ATE450256T1 AT07727719T AT07727719T ATE450256T1 AT E450256 T1 ATE450256 T1 AT E450256T1 AT 07727719 T AT07727719 T AT 07727719T AT 07727719 T AT07727719 T AT 07727719T AT E450256 T1 ATE450256 T1 AT E450256T1
Authority
AT
Austria
Prior art keywords
treatment
receptor antagonists
opioid receptor
compositions containing
kappa opioid
Prior art date
Application number
AT07727719T
Other languages
German (de)
English (en)
Inventor
Lars-Holger Hermann
Original Assignee
Emodys Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE102006015733A external-priority patent/DE102006015733A1/de
Priority claimed from DE102006016991A external-priority patent/DE102006016991A1/de
Application filed by Emodys Gmbh filed Critical Emodys Gmbh
Application granted granted Critical
Publication of ATE450256T1 publication Critical patent/ATE450256T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AT07727719T 2006-04-04 2007-04-03 Verwendung von zusammensetzungen enthaltend kappa-opioidrezeptor-antagonisten zur behandlung von dissoziativen störungen ATE450256T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102006015733A DE102006015733A1 (de) 2006-04-04 2006-04-04 Verwendung von Buprenorphin und Buprenorphin-Derivaten zur Herstellung eines Medikaments zur Behandlung von emotional instabiler Persönlichkeitsstörung, Alkoholabhängigkeit und/oder multipler Substanzabhängigkeit
DE102006016991A DE102006016991A1 (de) 2006-04-11 2006-04-11 Verwendung von kappa-Opioidrezeptor-Antagonisten zur Behandlung von dissoziativen Störungen
PCT/EP2007/053248 WO2007115975A2 (de) 2006-04-04 2007-04-03 Verwendung von zusammensetzungen enthaltend kappa-opioidrezeptor-antagonisten zur behandlung von dissoziativen störungen

Publications (1)

Publication Number Publication Date
ATE450256T1 true ATE450256T1 (de) 2009-12-15

Family

ID=38110094

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07727719T ATE450256T1 (de) 2006-04-04 2007-04-03 Verwendung von zusammensetzungen enthaltend kappa-opioidrezeptor-antagonisten zur behandlung von dissoziativen störungen

Country Status (17)

Country Link
US (1) US8063059B2 (enExample)
EP (1) EP2001456B1 (enExample)
JP (1) JP5128578B2 (enExample)
AT (1) ATE450256T1 (enExample)
AU (1) AU2007236003B2 (enExample)
CA (1) CA2646899C (enExample)
CY (1) CY1109862T1 (enExample)
DE (1) DE502007002185D1 (enExample)
DK (1) DK2001456T3 (enExample)
EA (1) EA014820B1 (enExample)
ES (1) ES2337622T3 (enExample)
HR (1) HRP20100113T1 (enExample)
PL (1) PL2001456T3 (enExample)
PT (1) PT2001456E (enExample)
RS (1) RS51211B (enExample)
SI (1) SI2001456T1 (enExample)
WO (1) WO2007115975A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7709522B2 (en) 2008-01-22 2010-05-04 Eli Lilly And Company Kappa selective opioid receptor antagonist
CA2933733A1 (en) * 2013-12-20 2015-06-25 Connie Sanchez Morillo Use of an opioid receptor antagonist with kappa-activity and vortioxetine for treatment of depressive disorder with melancholic features
US9192570B2 (en) 2013-12-20 2015-11-24 AntiOP, Inc. Intranasal naloxone compositions and methods of making and using same
AU2015253417B2 (en) 2014-04-28 2020-02-20 Dimerx, Inc. Pharmaceutically active dimers linked through phenolic hydroxyl groups
US10316021B2 (en) 2016-11-28 2019-06-11 Pfizer Inc. Heteroarylphenoxy benzamide kappa opioid ligands
US12161622B2 (en) 2021-05-04 2024-12-10 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
CA3254546A1 (en) 2022-03-07 2023-09-14 Janssen Pharmaceuticals, Inc. COMPOSITIONS CONTAINING ATICAPRANT
CN119156211A (zh) 2022-03-07 2024-12-17 杨森制药公司 用于治疗重性抑郁障碍的多晶型形式的阿替卡普兰

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5028612A (en) * 1990-03-22 1991-07-02 Hillel Glover Method for treating emotional numbness
US5780479A (en) * 1997-04-04 1998-07-14 Regents Of The University Of Minnesota Use of opioid antagonists to treat impulse-control disorders
EP1061924A1 (en) * 1998-03-09 2000-12-27 Trustees Of Tufts College Treatment of compulsive behaviours in man and animals
US20020045572A1 (en) 2000-08-15 2002-04-18 Cpd, Llc Method of treating the syndrome of type 2 diabetes in humans
EP1365756A2 (en) 2000-08-15 2003-12-03 Cpd, Llc Method of treating the syndrome of type 2 diabetes in humans
JP2004518654A (ja) * 2000-12-21 2004-06-24 ザ マクレーン ホスピタル コーポレーション 鬱病の治療法
US7666876B2 (en) * 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
CN100537564C (zh) * 2003-04-04 2009-09-09 麦克公司 代谢型谷氨酸受体-5的二芳基取代三唑调节剂
JP2007526328A (ja) * 2004-03-02 2007-09-13 ファルマシア コーポレーション 単独および抗うつ薬と組み合わせた形のＣｏｘ−２阻害剤によって精神障害を治療または予防するための方法および組成物
ME01072B (me) * 2004-05-26 2012-10-20 Inotek Pharmaceuticals Corp Derivati purina kao agonisti receptora adenozina a1 i postupci za njihovu upotrebu
WO2005117838A1 (en) * 2004-06-02 2005-12-15 Galephar M/F Stable oral pharmaceutical compositions of buprenorphine and derivatives

Also Published As

Publication number Publication date
DK2001456T3 (da) 2010-04-12
CA2646899C (en) 2014-05-06
CA2646899A1 (en) 2007-10-18
EA200802104A1 (ru) 2009-04-28
ES2337622T3 (es) 2010-04-27
SI2001456T1 (sl) 2010-04-30
PL2001456T3 (pl) 2010-05-31
AU2007236003B2 (en) 2012-10-18
RS51211B (sr) 2010-12-31
EP2001456A2 (de) 2008-12-17
EA014820B1 (ru) 2011-02-28
HRP20100113T1 (hr) 2010-04-30
WO2007115975A3 (de) 2008-02-14
JP2009532434A (ja) 2009-09-10
CY1109862T1 (el) 2014-09-10
PT2001456E (pt) 2010-03-03
AU2007236003A1 (en) 2007-10-18
US20090181999A1 (en) 2009-07-16
DE502007002185D1 (de) 2010-01-14
WO2007115975A2 (de) 2007-10-18
US8063059B2 (en) 2011-11-22
JP5128578B2 (ja) 2013-01-23
EP2001456B1 (de) 2009-12-02

Similar Documents

Publication Publication Date Title
EA201170624A1 (ru) Изоникотинамидные антагонисты рецепторов орексинов
ATE540944T1 (de) Pyridylpiperidinorexin-rezeptorantagonisten
CY1110882T1 (el) Ανταγωνιστες υποδοχεων ορεξινης υποκατεστημενης διαζεπανης
CY1111927T1 (el) Νεες ενωσεις ως διαμορφωτες υποδοχεα οπιοειδων
DE602005015577D1 (de) Harnstoff-antagonisten des p2y1-rezeptors zur behandlung von thromboseleiden
MA32898B1 (fr) Modulateurs allosteriques positifs du recepteur m1 d'arylmethylbenzoquinazolinone
DE502007002185D1 (de) Verwendung von zusammensetzungen enthaltend kappa-opioidrezeptor-antagonisten zur behandlung von dissoziativen störungen
DE602007006019D1 (de) Für die behandlung von durch den gpr38-rezeptor vermittelten krankheiten geeignete piperazinylderivate
EA200900048A1 (ru) Новые карбонилированные (аза)циклогексаны в качестве лигандов d3 рецептора дофамина
ATE469895T1 (de) Cgrp-rezeptorantagonisten
EA201100062A1 (ru) Соединения и способы модулирования рецепторов, связанных с белком g
UA92670C2 (ru) Пиразолиновые соединения и их фармацевтическое применение, композиция на их основе
UA106873C2 (uk) Сполуки заміщених діазепанів як антагоністи орексинових рецепторів
MX2009003645A (es) Azaciclilaminas n-sustituidas como antagonistas de histamina-3.
MX2009003981A (es) Agentes moduladores del receptor de calcio.
MA32943B1 (fr) Piperidine spiro pyrrolidione et piperidinone substituees, leur preparation et leur utilisation therapeutique
ATE542795T1 (de) Benzylpiperazinderivate als motilin- rezeptorantagonisten
ATE505468T1 (de) N-gebundene heterocyclische antagonisten des p2y1-rezeptors zur behandlung von thromboseleiden
DE602005027230D1 (de) Cgrp-rezeptorantagonisten
ATE455111T1 (de) Einen azepin-kern enthaltende antagonisten des histaminrezeptors
MX2009000762A (es) 4-arilalcoximetil-4-fenil piperidinas y su uso como antagonistas del receptor de neuroquinina para el tratamiento de trastornos del sistema nervioso central.
ATE541585T1 (de) Antikörper gegen il-5-rezeptor zur verwendung in der behandlung von endometriose.
HK1127349A (en) 4-arylalkoxymethyl-4-phenyl piperidines and their use as neurokinin receptor antagonists for the treatment of cns disorders